Profund Advisors LLC Has $145,000 Stock Holdings in Cogent Biosciences, Inc. $COGT

Profund Advisors LLC decreased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 42.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,157 shares of the technology company’s stock after selling 14,738 shares during the quarter. Profund Advisors LLC’s holdings in Cogent Biosciences were worth $145,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Strs Ohio acquired a new stake in Cogent Biosciences during the 1st quarter worth about $36,000. CWM LLC increased its position in shares of Cogent Biosciences by 11,869.9% in the first quarter. CWM LLC now owns 8,738 shares of the technology company’s stock worth $52,000 after acquiring an additional 8,665 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of Cogent Biosciences by 37.7% during the first quarter. E Fund Management Co. Ltd. now owns 15,670 shares of the technology company’s stock valued at $94,000 after acquiring an additional 4,290 shares during the period. Ieq Capital LLC purchased a new stake in shares of Cogent Biosciences in the 1st quarter valued at approximately $101,000. Finally, Corton Capital Inc. lifted its position in shares of Cogent Biosciences by 6.4% in the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company’s stock valued at $125,000 after acquiring an additional 1,046 shares in the last quarter.

Analyst Upgrades and Downgrades

COGT has been the topic of several research analyst reports. Raymond James Financial started coverage on shares of Cogent Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $30.00 price objective on the stock. Robert W. Baird raised their target price on Cogent Biosciences from $14.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Stifel Nicolaus upgraded Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Monday, November 10th. Leerink Partners increased their price objective on Cogent Biosciences from $18.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 10th. Finally, HC Wainwright raised their price objective on Cogent Biosciences from $21.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and an average target price of $32.33.

Cogent Biosciences Trading Down 0.9%

NASDAQ COGT opened at $33.54 on Monday. Cogent Biosciences, Inc. has a 1-year low of $3.72 and a 1-year high of $36.29. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $4.78 billion, a PE ratio of -20.45 and a beta of 0.41. The firm’s fifty day simple moving average is $16.50 and its 200-day simple moving average is $11.55.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. As a group, sell-side analysts anticipate that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.